Inventor · disambiguated record
Nasreen Jacobson
Also filed as: JACOBSON NASREEN
1 granted patent·7 pending applications·13 citations·filing 2003–2022
40Inventor score
Top patents by PatentIndex Score
8 records- 0178US7351407B2Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathiesALCON INC·Filed 2003·Granted Apr 1, 2008·13 cites·11 claims
- 0258US2024408267A1Compositions of decidua tissue and uses thereofOSIRIS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0356US2008176964A1Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathiesALCON RES LTD·Filed 2008·Application pending·0 cites
- 0447US2006020001A1Use of cathepsin k inhibitors for the treatment of glaucomaSHEPARD ALLAN·Filed 2003·Application pending·0 cites
- 0546US2006275797A1Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disordersALCON MFG LTD·Filed 2006·Application pending·0 cites
- 0646US2012101160A1Use of chemical chaperones to treat glaucoma caused by misfolded or misprocessed proteinsSHEPARD ALLAN·Filed 2005·Application pending·0 cites
- 0745US2011092523A1Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathiesALCON RES LTD·Filed 2010·Application pending·0 cites
- 0843US2005159432A1Short form c-Maf transcription factor antagonists for treatment of glaucomaALCON INC·Filed 2004·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Nasreen Jacobson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →